FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2623014794> ?p ?o ?g. }

• W2623014794 endingPage "2127" @default.
• W2623014794 startingPage "2116" @default.
• W2623014794 abstract "ABSTRACT Macrophages have established roles supporting bone formation. Despite their professional phagocytic nature, the role of macrophage phagocytosis in bone homeostasis is not well understood. Interestingly, apoptosis is a pivotal feature of cellular regulation and the primary fate of osteoblasts is apoptosis. Efferocytosis (phagocytosis of apoptotic cells) is a key physiologic process for the homeostasis of many tissues, and is associated with expression of osteoinductive factors. To test effects of macrophage depletion and compromised phagocytosis on bone, 16‐week‐old male C57BL/6J mice were treated with trabectedin—a chemotherapeutic with established anti‐macrophage effects. Trabectedin treatment reduced F4/80+ and CD68+ macrophages in the bone marrow as assessed by flow cytometry, osteal macrophages near the bone surface, and macrophage viability in vitro. Trabectedin treatment significantly reduced marrow gene expression of key phagocytic factors ( Mfge8 , Mrc1 ), and macrophages from treated mice had a reduced ability to phagocytose apoptotic mimicry beads. Macrophages cultured in vitro and treated with trabectedin displayed reduced efferocytosis of apoptotic osteoblasts. Moreover, efferocytosis increased macrophage osteoinductive TGF‐β production and this increase was inhibited by trabectedin. Long‐term (6‐week) treatment of 16‐week‐old C57BL/6J mice with trabectedin significantly reduced trabecular BV/TV and cortical BMD. Although trabectedin reduced osteoclast numbers in vitro, osteoclast surface in vivo was not altered. Trabectedin treatment reduced serum P1NP as well as MS/BS and BFR/BS, and inhibited mineralization and Runx2 gene expression of osteoblast cultures. Finally, intermittent PTH 1‐34 (iPTH) treatment was administered in combination with trabectedin, and iPTH increased trabecular bone volume fraction (BV/TV) in trabectedin‐treated mice. Collectively, the data support a model whereby trabectedin significantly reduces bone mass due to compromised macrophages and efferocytosis, but also due to direct effects on osteoblasts. This data has immediate clinical relevance in light of increasing use of trabectedin in oncology. © 2017 American Society for Bone and Mineral Research." @default.
• W2623014794 created "2017-06-15" @default.
• W2623014794 creator A5007702426 @default.
• W2623014794 creator A5008100195 @default.
• W2623014794 creator A5010672369 @default.
• W2623014794 creator A5021299204 @default.
• W2623014794 creator A5035424698 @default.
• W2623014794 creator A5036708496 @default.
• W2623014794 creator A5074901217 @default.
• W2623014794 creator A5077110704 @default.
• W2623014794 date "2017-08-31" @default.
• W2623014794 modified "2023-10-05" @default.
• W2623014794 title "Bone Mass Is Compromised by the Chemotherapeutic Trabectedin in Association With Effects on Osteoblasts and Macrophage Efferocytosis" @default.
• W2623014794 cites W1508394416 @default.
• W2623014794 cites W1802397357 @default.
• W2623014794 cites W1822656157 @default.
• W2623014794 cites W1977583598 @default.
• W2623014794 cites W2002353852 @default.
• W2623014794 cites W2014220117 @default.
• W2623014794 cites W2024884314 @default.
• W2623014794 cites W2044284047 @default.
• W2623014794 cites W2051926344 @default.
• W2623014794 cites W2055404740 @default.
• W2623014794 cites W2055489437 @default.
• W2623014794 cites W2066749771 @default.
• W2623014794 cites W2067843805 @default.
• W2623014794 cites W2075292460 @default.
• W2623014794 cites W2081603767 @default.
• W2623014794 cites W2087378917 @default.
• W2623014794 cites W2096425957 @default.
• W2623014794 cites W2096616470 @default.
• W2623014794 cites W2096627331 @default.
• W2623014794 cites W2101773788 @default.
• W2623014794 cites W2107277218 @default.
• W2623014794 cites W2111571798 @default.
• W2623014794 cites W2117881262 @default.
• W2623014794 cites W2122693935 @default.
• W2623014794 cites W2127738873 @default.
• W2623014794 cites W2130035132 @default.
• W2623014794 cites W2136792060 @default.
• W2623014794 cites W2138548105 @default.
• W2623014794 cites W2146766929 @default.
• W2623014794 cites W2151181789 @default.
• W2623014794 cites W2153350681 @default.
• W2623014794 cites W2192080449 @default.
• W2623014794 cites W2342035050 @default.
• W2623014794 cites W2419462164 @default.
• W2623014794 cites W2517745633 @default.
• W2623014794 cites W4235300003 @default.
• W2623014794 doi "https://doi.org/10.1002/jbmr.3196" @default.
• W2623014794 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5640484" @default.
• W2623014794 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28600866" @default.
• W2623014794 hasPublicationYear "2017" @default.
• W2623014794 type Work @default.
• W2623014794 sameAs 2623014794 @default.
• W2623014794 citedByCount "24" @default.
• W2623014794 countsByYear W26230147942017 @default.
• W2623014794 countsByYear W26230147942018 @default.
• W2623014794 countsByYear W26230147942019 @default.
• W2623014794 countsByYear W26230147942020 @default.
• W2623014794 countsByYear W26230147942021 @default.
• W2623014794 countsByYear W26230147942022 @default.
• W2623014794 countsByYear W26230147942023 @default.
• W2623014794 crossrefType "journal-article" @default.
• W2623014794 hasAuthorship W2623014794A5007702426 @default.
• W2623014794 hasAuthorship W2623014794A5008100195 @default.
• W2623014794 hasAuthorship W2623014794A5010672369 @default.
• W2623014794 hasAuthorship W2623014794A5021299204 @default.
• W2623014794 hasAuthorship W2623014794A5035424698 @default.
• W2623014794 hasAuthorship W2623014794A5036708496 @default.
• W2623014794 hasAuthorship W2623014794A5074901217 @default.
• W2623014794 hasAuthorship W2623014794A5077110704 @default.
• W2623014794 hasBestOaLocation W26230147941 @default.
• W2623014794 hasConcept C126322002 @default.
• W2623014794 hasConcept C134018914 @default.
• W2623014794 hasConcept C136948725 @default.
• W2623014794 hasConcept C142724271 @default.
• W2623014794 hasConcept C160448771 @default.
• W2623014794 hasConcept C168261976 @default.
• W2623014794 hasConcept C170493617 @default.
• W2623014794 hasConcept C185592680 @default.
• W2623014794 hasConcept C202751555 @default.
• W2623014794 hasConcept C203014093 @default.
• W2623014794 hasConcept C2776033226 @default.
• W2623014794 hasConcept C2778260815 @default.
• W2623014794 hasConcept C2778629024 @default.
• W2623014794 hasConcept C2779244956 @default.
• W2623014794 hasConcept C2780007613 @default.
• W2623014794 hasConcept C2780752271 @default.
• W2623014794 hasConcept C502942594 @default.
• W2623014794 hasConcept C55493867 @default.
• W2623014794 hasConcept C71924100 @default.
• W2623014794 hasConcept C98274493 @default.
• W2623014794 hasConceptScore W2623014794C126322002 @default.
• W2623014794 hasConceptScore W2623014794C134018914 @default.
• W2623014794 hasConceptScore W2623014794C136948725 @default.
• W2623014794 hasConceptScore W2623014794C142724271 @default.
• W2623014794 hasConceptScore W2623014794C160448771 @default.

• next